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mortality worldwide, available funding falls far short of that required
for effective control. Economic and spillover consequences of invest-
ments in the treatment of tuberculosis are unclear, particularly when
steep gradients in the disease and response are linked by population
movements, such as that between Papua New Guinea (PNG) and the
Australian cross-border region. Objective: To undertake an economic
evaluation of Australian support for the expansion of basic Directly
Observed Treatment, Short Course in the PNG border area of the South
Fly from the current level of 14% coverage. Methods: Both cost-utility
analysis and cost-beneﬁt analysis were applied to models that allow
for population movement across regions with different characteristics
of tuberculosis burden, transmission, and access to treatment. Cost-
beneﬁt data were drawn primarily from estimates published by the
World Health Organization, and disease transmission data were
drawn from a previously published model. Results: Investing $16ee front matter Copyright & 2015, International S
r Inc.
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University, Canberra, ACT 2601, Australia.million to increase basic Directly Observed Treatment, Short Course
coverage in the South Fly generates a net present value of roughly $74
million for Australia (discounted 2005 dollars). The cost per disability-
adjusted life-year averted and quality-adjusted life-year saved for PNG
is $7 and $4.6, respectively. Conclusions: Where regions with major
disparities in tuberculosis burden and health system resourcing are
connected through population movements, investments in tuber-
culosis control are of mutual beneﬁt, resulting in net health and
economic gains on both sides of the border. These ﬁndings are likely
to inform the case for appropriate investment in tuberculosis control
globally.
Keywords: Australia, cost-beneﬁt analysis, cost-utility analysis, DOTS,
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Copyright & 2015, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Tuberculosis (TB) remains a major health threat, being the
second leading cause of death from an infectious disease world-
wide. Two decades after the declaration of TB as a global health
emergency by the World Health Organization (WHO), in 1993, the
ﬁnancial resources needed in the ﬁght against TB remain enor-
mous [1]. Existing and inadequate funding levels are largely
because most of the expenses incurred in the control of TB are
funded out of increasingly tight national budgets, while the
prevalence of TB is skewed toward poor developing countries
who can least afford it [1].
As a long-lived airborne communicable disease, TB takes its
toll not only on developing countries where prevalence is high
but also on developed countries, partly due to the mobility of the
disease. In developed countries, foreign-born immigrants and
travelers to areas with a high burden of TB account for an
increasing proportion of all new cases of TB [2–5]. That said,
measures taken thus far to prevent TB in developed countries are
typically conﬁned within given borders to the home country[6–10]. Analysis suggests that strengthening TB programs in
countries with a higher burden of TB, where most immigrants
and visitors come from, thus reducing the levels of transmission
from this source, may generate signiﬁcant domestic gains for
developed countries [11]. Past modeling of such transmission and
interventions, however, has not accounted for the impact of
citizens from developed countries traveling to high-incidence
countries. Therefore, there is a need to develop models that
account for the impact of two-way population movements to
quantify more accurately the beneﬁts of measures to reduce TB
incidence occurring from speciﬁc two-way travel between areas
with a high and low burden of TB.
We address this gap in the literature by evaluating the
Australian-funded control of TB in Papua New Guinea (PNG), its
closest neighbor. It is worth noting that Australia has one of the
most well-resourced health service systems and the lowest
burden of TB in the world, while PNG is a poor developing
country with many health system challenges, including a very
high burden of TB. Our economic evaluation draws on the
perspectives of both the broader society and the health sector.ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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countries, which covers the Torres Strait Islands (TSI) of Australia
and the South Fly district of PNG. Here, movements of people
between the two communities for traditional activities are
frequent and largely unrestricted because of a special treaty
signed between the two countries, facilitating cross-border move-
ment for traditional purposes. For this reason, the area is a
principal focus for concerns related to ongoing importation of
TB from PNG. We consider an Australian-funded expansion of a
basic Directly Observed Treatment, Short Course (or basic DOTS)
program in the South Fly, which covers detection and treatment
of patients with infectious (pulmonary) TB. This intervention is
the standard recommended by the WHO, including that for
resource-poor areas such as the South Fly where TB prevalence
and incidence are high, while the prevailing TB programs and
health services in place are particularly weak [12–14].Fig. 1 – Schematic of subpopulations in the metapopulation for
South Fly and Torres Strait Islands. Note that homogeneous
mixing occurs on each side of the border between Pop(1,1) and
Pop(1,2) and between Pop(2,1) and Pop(2,2).Methods
We undertook an economic evaluation of Australia’s support for
the control of TB in PNG based on an epidemiological model that
captures the patterns of disease transmission between the two
regions. Our evaluation draws on the perspective of both the
heath sector and society. That is, we apply a cost-utility analysis
(CUA) and a cost-beneﬁt analysis (CBA)—the principal tools used
to guide resource allocation in the health sector and the whole
economy, respectively—in our evaluation. Being identical in
measuring costs, these two approaches differ in the measure-
ment of beneﬁts. In particular, CUA measures health improve-
ments due to an intervention by a combination of duration and
the quality of life saved while CBA measures them in monetary
terms. As such, CUA allows the comparison of one intervention
against another in terms of the health gains it achieves while
CBA allows for the comparison of beneﬁts aside from health
gains alone. Each has its own advantages, and by using both, we
address the limitations in applying only one method.
Interventions and Comparator
The interventions we assess in our article focus on the expansion
of the basic DOTS program in PNG’s South Fly from the current
level of 14% coverage to various levels including 30%, 50%, 65%,
80%, and 95% coverage. These interventions were simulated to
last for 20 years, starting from 2014. The duration of 20 years was
used because latent infections can last a lifetime, and changes in
prevalence due to differences in control are likely to remain after
a long duration, such as 20 years. The health outcomes and costs
generated by expanding the basic DOTS coverage were calculated
in relation to those generated by the comparator, which was to
maintain the current 14% coverage. Differences in costs and
beneﬁts under the interventions and the comparator served as
inputs to our economic evaluation.
We also explored the effect of a delay between detection and
treatment. Existing literature on other developing countries
suggests that 4 weeks is correct [15]. In the South Fly, however,
a delay of 12 weeks seems more realistic because the commun-
ities here are relatively isolated and health services are poor [16].
Therefore, we present results with 1) a delay of 12 weeks, as a
realistic case for the South Fly; 2) 4 weeks, using an estimate of
the average delay in developing countries; and 3) 1 week, a
possible ultimate goal for the South Fly. Changes in the delay
between detection and treatment were considered in conjunction
with changes in the expansion of the basic DOTS coverage
because this alteration alone does not yield signiﬁcant changes
in health beneﬁts due to the low coverage of the current basic
DOTS program in the South Fly.Finally, it is worth noting that we consider only the South Fly
and the TSI instead of the whole of Australia and PNG in our
model because the frequent and relatively unscreened move-
ments between the two countries occur between these two
communities because of an existing treaty. This situation makes
the region unique and a focus therefore of special concern related
to a possible spread of TB from PNG to Australia.Epidemiological Model
Our epidemiological model was built using a combination of
metapopulation and compartment modeling techniques, follow-
ing Hickson et al. [17]. The former not only allows for each
country or subpopulation to have its own dynamics and attrib-
utes but also for interaction (albeit limited) between these
subpopulations [18–20]. This feature is particularly important to
our analysis because there are major disparities in the burden
and transmission of TB, as well as access to treatment between
the two regions, which exist within the context of physical and
cultural proximity, and with the established treaties for popula-
tion movements in place. There are four subpopulations in the
model: 1) Australians in Australia—Pop (1,1); 2) Australians in
PNG—Pop (2,1); 3) Papua New Guineans in PNG—Pop (2,2); and 4)
Papua New Guineans in Australia—Pop (1,2) (Fig. 1). A compart-
ment technique was used to categorize people in each subpopu-
lation by health state to distinguish uninfected from infected
persons, latent infection from active infectious (pulmonary) and
noninfectious (extrapulmonary) TB, and those individuals being
treated for the ﬁrst time from those being re-treated after the ﬁrst
treatment failure (Fig. 2).
Transition between health states, interaction of subpopula-
tions due to travel as well as dynamics through time in the model
are captured by systems of nonlinear ordinary differential equa-
tions provided in the Supplementary Material found at http://dx.
doi.org/10.1016/j.jval.2014.11.008. The parameters and their val-
ues used in the model reﬂect the current and historical situation
in the two regions. For example, we started running the model
with a single infectious case in PNG from the year 1800 until the
epidemic stabilized, and the transmission rates were determined
so that the incidence, prevalence, death rate, and population
match the available data [17]. Based on this run, the initial
conditions in terms of distributions of subpopulations across
various health states were determined for intervention analysis.
Some assumptions were made when we experimented with
the interventions. First, we assumed that the rates of travel
undertaken by Australians and Papua New Guinean people,
estimated using two-way border crossings reported by the
Department of Immigration and Citizenship [21], remained con-
stant throughout the period of analysis. Second, we assumed that
the detection rate, which determines the coverage of a basic
DOTS program, increased following a logarithmic function to
capture the fact that detection is easiest to improve on when it is
initially low and becomes increasingly difﬁcult to enhance with
Fig. 2 – The single region disease model. I, infectious
(pulmonary) TB; L, latently infected; N, noninfectious
(extrapulmonary) TB; S, susceptible, T1 , infectious TB being
treated for the ﬁrst time; T2 , infectious TB being re-treated.
The parameters are summarized in Appendix Table A in the
Supplementary Material found at http://dx.doi.org/10.1016/j.
jval.2014.11.008. Here λ ¼ β (I þ T1 þ T2)/P.
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assumed to be fully achieved only after 4 years since its
inception, given the current weak state of the health system in
PNG. For other coverage levels, a proportion of 4 years
was assumed on the basis of their extensiveness. Details on
parameters, their values, and sources are provided in the
Supplementary Material found at http://dx.doi.org/10.1016/j.jval.
2014.11.008 , while needed assumptions are discussed in detail in
Hickson et al. [17]. Our model was calibrated in Matlab version
R2012b with results reported at a 5-day interval.Economic Evaluation
To evaluate Australia’s support for the control of TB in PNG, we
further considered interventions, be it under CBA or CUA, from
two different angles. The ﬁrst angle is solely from the viewpoint
of Australians—termed an “Australian viewpoint” hereafter.
Here, Australia was assumed to cover the costs on both sides of
the border while taking into account only its own beneﬁts. Put
differently, we aimed to provide information to Australian tax-
payers on whether it was worthwhile for them to invest in
controlling TB in PNG for their own beneﬁt.
For the second angle, we provided information to Australia as
a donor country that tried to increase its aid effectiveness over-
seas. As a result, the focus from this viewpoint was on costs and
beneﬁts incurred in PNG only—we call this the “Overseas Devel-
opment Assistance (ODA) viewpoint” hereafter.
Finally, the cost or beneﬁt of each intervention, regardless of
being drawn from a CBA or CUA approach or from an Australian
or ODA viewpoint, is the difference in accumulated costs or
beneﬁts under the intervention and the comparator. All future
costs and outcomes were discounted at a rate of 3% [22,23] and
reported in 2005 dollars unless speciﬁed otherwise.Estimating Costs
The cost of running a basic DOTS program is ﬁrst calculated, be it
under the various interventions or the comparator, and includes
covered diagnosis, treatment, and program management. Patient
time and transportation were not considered in our article. For
diagnosis, we used assumptions in the WHO toolkit for planning
and budgeting for TB control in PNG [24] and Baltussen et al. [25].
Unit costs of diagnosis (i.e., X-rays and smear tests) for TSI and
the South Fly were obtained from WHO estimates for America
and Indonesia, respectively [26]. In terms of treatment, we
followed WHO guidelines. That is, in the absence of a
multidrug-resistant tuberculosis program, ﬁrst-time treated
patients were provided with a 6-month treatment while re-
treated patients were provided with an 8-month treatment [13].
Drugs needed for treatment were estimated using prices from the
Global Drugs Facility [27]. Because TB treatment needs to be
directly observed and a clear guideline by the WHO on this matter
is not available, we used assumptions from Baltussen et al. [25]
on the frequency of health center visits. Unit costs for health
center visits are those provided by the WHO [28] for the global
health region to which Australia and PNG belong, respectively.
Finally, cost estimates used for program management and super-
vision were those for the Sear-D region (the Sear-D region is
deﬁned by the WHO to include Bangladesh, Bhutan, the Demo-
cratic Peoples Republic of Korea, India, Maldives, Myanmar, and
Nepal) because data are not available for Australia, PNG, or the
Paciﬁc region. It is worth noting that the cost per patient with TB
in the South Fly varied relative to the level of basic DOTS
coverage but it remained constant in TSI due to the full basic
DOTS coverage already in place there. Detailed costs per patient
with TB are provided in the Supplementary Material found at
http://dx.doi.org/10.1016/j.jval.2014.11.008.
Estimating Beneﬁts
The beneﬁt in CUA was measured by the two most commonly
used metrics, quality-adjusted life-years (QALYs) and disability-
adjusted life-years (DALYs) [29]. The number of QALYs lived by an
individual in 1 year is the product of 1 year and his or her quality-
of-life weight, which is within the range [0,1], with 0 being dead
and 1 having perfect health. This weight is typically developed
using preferences drawn from the general public or patients and
applied uniformly to all individuals. In our article, it was 0.68 for
patients with TB [30].
Although being conceptually similar, DALY differs from QALY
in at least three important ways. First, its so-called disability
weight, which is also bounded by [0,1], has a reverse order, with 1
now representing death and 0 implying perfect health. Second,
the weight is hump-shaped, being the highest for people of
working age [31]. In our article, it lies in the range 0.26 to 0.29
[31]. Last and most importantly, in contrast to the quality-of-life
weight, the disability weight was developed from person trade-
off scores given by a panel of health care workers, thereby
reﬂecting preferences of the society.
It follows that we needed information on life expectancy and
the demographic structure of individuals distributed by health
state in each subpopulation to calculate DALY and QALY. Cali-
brating an epidemiological model to be solved for outcomes
having this information is computationally complicated and
inefﬁcient. As a result, we integrated this information into model
outcomes after the model was solved. The population demo-
graphic structures of Australia and PNG changed in line with
projections by the Australian Bureau of Statistics [32] and the
United Nations [33], respectively. The age and sex of patients
with TB in each respective region stayed constant at the average
of their estimates for 2004 to 2010 when data are available [34–
36]. The life expectancy of an Australian was taken from the life
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 1 8 0 – 1 8 8 183table 2008–2010 estimated by the Australian Bureau of Statistics
[37], while that for a Papua New Guinean was taken from the life
table 2011 by the WHO [38].
To assign money values to health outcomes in the CBA, we
used a stated-preference method. This is the most widely used
method to measure underlying consumer demand and valuation
for nonmarket goods such as health beneﬁts [29]. For example,
respondents are asked to think about the contingency of an
actual market for a health beneﬁt, say a QALY, and then to reveal
the maximum they would be willing to pay for it. This approach
dominates the other two general methods including human
capital and revealed preference measures for two reasons. First,
the human capital approach is often criticized for being incon-
sistent with the theoretical foundation of CBA because it offers a
narrow view of the consequences of an intervention to impacts
on labor productivity [39]. Also, the wage rates, which reﬂect
marginal labor productivity in the human capital approach,
embed inherent inequities in the labor market such as sex and
race discrimination [29]. The latter, the revealed preference
approach, examines the relationship between particular health
risks associated with a hazardous job and the wage rates that
individuals require to accept the job [40]. Although this approach
is consistent with the standard welfare economics framework
and based on actual consumer choices, its estimation is very
context and job speciﬁc [29].
The monetized beneﬁt of each intervention in our article is
the area under the demand curve for QALY for the QALY gain due
to each intervention. Using a Riemann sum, this area can be
approximated as follows:
B¼ ∑
N
i¼1
WTPi  ΔQALY ð1Þ
where B is the present beneﬁt of each intervention, WTPi is the
willingness to pay (WTP) for an additional QALY, and ΔQALY is a
small change in QALY gained. Although the “law of demand”
would suggest a negative association between WTPi and QALY,
evidence on this relationship so far is mixed: some found an
inverse relationship, for example, Pinto-Prades et al. [41],
whereas others suggested insensitivity of the WTP with respect
to the size of the health outcome, for example, Olsen et al. [42].
Acknowledging that the theory in consistently estimating WTP
per QALY is yet to be standardized [41,43–45], our approach is to
provide the best possible analysis given the information available
to us now. That is, we used the recent estimate on Australians’
WTP for an additional QALY by Shiroiwa et al. [46], which is
constant, in the absence of a reliable estimated form of WTPi as a
function of QALYi in Australia and elsewhere. Likewise, for Papua
New Guineans, we used gross domestic product (GDP) per capita
as a proxy of their WTP per an additional QALY due to data
unavailability.
Equation 1 is therefore simpliﬁed to
B ¼ WTP ΔQALY
where WTP is a constant WTP for an additional QALY and ΔQALY
is the total change in the health outcome due to an intervention.
Note that we cannot use DALY to measure health outcomes in
monetary terms because its disability weight reﬂects the society’s
(not the consumer’s) preferences.
Evaluation Criteria
Evaluation criteria used for CUA are cost per QALY saved and cost
per DALY averted. For the former, the benchmark to decide
whether an intervention is cost-effective is the cost-
effectiveness threshold by elected or appointed decision-
making bodies [47]. Admittedly, none of the decision-making
bodies in Australia or elsewhere has speciﬁed or conﬁrmed anexplicit threshold [44,48,49]. Nonetheless, there has been evi-
dence that a threshold exists implicitly, being a range of costs per
QALY with the probability of rejection increasing with the cost
[50–52]. Furthermore, although this threshold reﬂects a societal
perspective in making choices in resource allocation, one could
argue that individual perspectives would serve as the basis for
formulating a consistent and transparent threshold [46,53,54]. As
a result, we used the range of AU$35,000 to AU$120,000 as a
threshold for Australia suggested by Shiroiwa et al. [46], where
the cost per QALY being below the lower bound or above the
upper bound is likely associated with acceptance or rejection by
decision-making bodies, respectively. This range, especially the
lower bound, is comparable to the range of AU$40,000 to AU
$80,000 estimated by George et al. [52] who analyzed the deci-
sions on new drugs made by the Pharmaceutical Beneﬁts Advi-
sory Committee in Australia from 1991 to 1996. It is also in line
with “conventional ranges” in the United Kingdom (£20,000–
£30,000) [51] and the United States (US$50,000– US$100,000) [44].
For cost per DALY averted, we used GDP per capita as the
benchmark suggested by the WHO [55–57]. Accordingly, if the cost
per DALY is less than GDP per capita, the intervention is
considered highly cost-effective. Finally, in CBA, the criterion is
net present value (NPV), which is the difference between the
present values of all beneﬁts and costs. An intervention is
recommended if it has a positive NPV. Furthermore, interven-
tions are ranked on the basis of how high their NPVs are.Results
There are direct beneﬁts for TSI from expanding basic DOTS
coverage in South Fly as shown in the epidemiological model
outcomes presented in Table 1. For example, an expansion of
basic DOTS to 30% would result in 5% and 0.3% reductions in TB
prevalence and TB-related deaths in TSI, respectively (columns 4
and 6). From an ODA perspective, these reductions are more
substantial, being 24% and 4% in South Fly (columns 3 and 5).
Furthermore, for both regions, the more extensive the expansion
is, the higher the accrued beneﬁts are. Indeed, reductions in TB
prevalence and deaths due to TB in both regions are more than
double under a 95% coverage as compared with the one under a
30% coverage. Although the changes in deaths due to TB in TSI
are relatively small, they are signiﬁcant in South Fly, ranging
from 3% to 9%.
Results from economic evaluation (Table 2) corroborate the
ones from the epidemiological model. Indeed, all NPVs are
positive (columns 3 and 7), suggesting that all interventions are
worthwhile regardless of the expansion level or how long the
delay between detection and treatment would be. What is
more, the most striking result to emerge from Table 2 is that
the intervention cost increases with the basic DOTS expansion
level (columns 3 and 7) but at a much slower rate than does the
NPV (columns 4 and 8). In other words, the health beneﬁt
increases faster than the cost and this result is true regardless
of whether one considers the Australian viewpoint or the ODA
viewpoint.
From an Australian viewpoint, a 95% basic DOTS expansion in
South Fly would be the most preferred intervention based on a
CBA principle of choosing the highest NPV (column 4). Indeed,
with a $16 million intervention over a 20-year period, or about
$800,000 per year, a 95% basic DOTS expansion in South Fly
would generate about $74 million for Australia. There are two
main reasons why NPV is the highest under this intervention.
The ﬁrst reason is the high Australian WTP per QALY, which in
fact reﬂects how costly it would be to have TB in Australia. The
second reason is the economies-of-scale effect in expanding the
basic DOTS coverage in South Fly, and more importantly, the
Table 1 – Percentage change in prevalence and deaths due to TB under interventions relative to the comparator
of 14% basic DOTS coverage, after 20 y (2014–2034), for Papua New Guineans in South Fly and Australians in TSI.
Interventions Prevalence (%) Deaths due to TB (%)
δmax (%) 1/θ (wk) South Fly TSI South Fly TSI
30 1 23.2 5.0 3.9 0.3
4 22.5 4.9 3.5 0.3
12 20.8 4.6 3.3 0.3
50 1 39.3 8.6 6.3 0.5
4 38.3 8.4 6.2 0.5
12 35.6 8.0 5.8 0.5
65 1 46.3 10.2 7.5 0.7
4 45.4 10.0 7.4 0.6
12 42.2 9.5 7.0 0.6
80 1 51.3 11.3 8.4 0.7
4 50.16 11.1 8.3 0.7
12 46.9 10.6 7.8 0.7
95 1 54.9 12.2 9.1 0.8
4 53.71 12.0 8.9 0.8
12 50.3 11.4 8.4 0.7
Note. The basic DOTS coverage (δmax) and delay in treatment (1/θ) were both varied.
DOTS, Directly Observed Treatment, Short Course; TB, tuberculosis; TSI, Torres Straits Islands.
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with detecting and controlling an infectious disease such as
TB early.
In a CUA framework, a 95% basic DOTS expansion in South Fly
over a 20- year period is considered very cost-effective for
Australia. In particular, it would avert about 1500 DALYs or
2000 QALYs for Australia. With the average cost per DALY averted
of about $11,000 (column 5), the cost of this intervention is far
lower than the common threshold GDP per capita of about
$49,000 for Australia, thereby being highly cost-effective. Like-
wise, the average cost per QALY saved of about $7900 (column 6)
is much lower than the lower bound of $35,000 suggested by
Shiroiwa et al. [46] or the lower bound of $40,000 estimated by
George et al. [52]. Putting this all together, a 95% basic DOTS
expansion in South Fly appears as the best intervention for
Australia under both CUA and CBA frameworks.
As for the effect of delay between detection and treatment,
considerable gains were made if treatment initiation was not
delayed, particularly in situations of high program coverage.
For example, if treatment initiation reduces from 12 weeks to 4
weeks, the cost per QALY saved at the 95% coverage would fall
by about $700 while the one at the 30% coverage would fall by
only about $400 (column 6). In terms of NPV, this reduction in
treatment initiation implies a gain of about $5 million and $2
million, respectively, for the programs at these two coverage
levels. These gains in NPVs are substantial with respect to
program costs of $16 million and $3 million. This result
suggests that the cost of interventions for improving treat-
ment initiation times (which was not assessed in our model-
ing because of data unavailability) is likely to result in
net gains.
Finally, from an ODA viewpoint, which focuses only on the
costs and beneﬁts incurred in PNG only, the cost per QALY saved
and the cost per DALY averted fall sharply (columns 9 and 10).
Indeed, it would cost from $2.3 to $4.6 per QALY saved and from
$3.5 to $7 per DALY averted. The sharp fall in these costs come
from remarkable gains accruing to South Fly from this basic
DOTS expansion. This result is plausible because gains from basic
DOTS expansion are typically large at a low coverage level. As
such, this intervention ranks extremely well among the “top ten
best health buys” in developing countries [58]. In summary, thereare clear beneﬁts for Australia regardless of the viewpoint and
evaluation approach one takes.Sensitivity and Uncertainty Analyses
Before turning to our discussion, we subject our results to
sensitivity and uncertainty analyses. The approach here is two-
fold, concentrating on two concerns. The ﬁrst concern is possible
uncertainty in the underlying parameters for our epidemiological
model, which arises because of the assumptions we made. The
second concern is about uncertainty in the estimates for eco-
nomic evaluation indicators due to the unavailability of some
local costs, as discussed in the section on estimating costs.
To address the ﬁrst concern, we conducted a sensitivity
analysis of the model parameters using the standard combina-
tion (see, e.g., [59–62]) of Latin hypercube sampling for efﬁcient
sampling of the parameter space and the multivariate partial
rank correlation coefﬁcient analysis, in which values with mag-
nitudes close to 1 are most important and the sign is the
correlation. When considering the cumulative number of TB
cases, the partial rank correlation coefﬁcient values after 20 years
are shown in Figure 3. The most inﬂuential parameter is the rate
of latently infected individuals becoming clinically active (ν),
followed by the transmission rate (β) and the proportion devel-
oping infectious TB (ρ) in PNG.
For the second concern, we calculated lower and upper
bounds for our estimates by increasing and reducing the unit
cost per patient with TB by 30%. The reason for this is that we
used available estimates from countries/regions that are the
most similar to the countries/regions of our interest in terms of
the economic development level, living standard, and geograph-
ical proximity in the absence of better data. For example, our
costs of TB program management and supervision were based on
WHO estimates for the SEAR-D region, which is located next to
and is possibly of the most similar development level with the
regions that Australia and PNG belong to, among all WHO-
deﬁned global burden of disease regions. But it is hard to know
for certain whether those data substitutes are overestimates or
underestimates of the true costs of these activities in our region
of interest.
Table 2 – Cost per DALY, QALY, and NPV (USD 2005) of interventions relative to the comparator of 14% basic DOTS coverage after 20 y (2014–2034) for
Papua New Guineans in South Fly and Australians in TSI.
Interventions TSI South Fly
Basic
DOTS
coverage
(%)
1/θ
(wk)
Total
discounted
cost (million)
NPV
(million)
Cost per
DALY
(thousand)
Cost per
QALY
(thousand)
Total
discounted
cost (million)
NPV (billion) Cost per
DALY
Cost per
QALY
30 1 3.22 (2.25–4.19) 32.76 (33.73–31.80) 5.56 (3.89–7.23) 3.89 (2.72–5.06) 3.23 (2.26–4.20) 3.14 (3.15–3.14) 3.41 (2.38–4.43) 2.24 (1.57–2.91)
4 3.25 (2.27–4.22) 32.02 (32.99–31.04) 5.72 (4.01–7.44) 4 (2.80–5.20) 3.26 (2.28–4.24) 3.08 (3.09–3.08) 3.5 (2.45–4.55) 2.3 (1.61–3.00)
12 3.33 (2.33–4.33) 29.77 (30.77–28.77) 6.25 (4.37–8.12) 4.37 (3.06–5.68) 3.34 (2.34–4.34) 2.91 (2.91–2.90) 3.81 (2.67– 4.95) 2.51 (1.76–3.26)
50 1 8.23 (5.76–10.69) 55.32 (57.78–52.85) 8.05 (5.64–10.47) 5.63 (3.94–7.31) 8.24 (5.77–10.72) 5.5 (5.51–5.50) 4.97 (3.48–6.46) 3.27 (2.29–4.25)
4 8.31 (5.82–10.80) 54.06 (56.55–51.57) 8.29 (5.80–10.77) 5.79 (4.05–7.53) 8.33 (5.83–10.82) 5.41 (5.41–5.41) 5.11 (3.57–6.64) 3.36 (2.35–4.36)
12 8.55 ( 5.99–11.12) 50.26 (52.83–47.70) 9.04 (6.32–11.75) 6.32 (4.42–8.21) 8.57 (6.00–11.14) 5.12 (5.12–5.11) 5.55 (3.88–7.21) 3.65 (2.55–4.74)
65 1 12.38 (8.67–16.10) 63.7 (67.41–59.98) 10.13 (7.09–13.17) 7.07 (4.95–9.19) 12.4 (8.68–16.12) 6.59 (6.59–6.58) 6.25 (4.37–8.12) 4.1 (2.87–5.34)
4 12.51 (8.76–16.27) 62.24 (65.99–58.49) 10.42 (7.30–13.54) 7.27 (5.09–9.46) 12.54 (8.77–16.30) 6.48 (6.48–6.48) 6.42 (4.49–8.34) 4.22 (2.95–5.48)
12 12.9 (9.03–16.77) 57.77 (61.64–53.90) 11.35 (7.94–14.75) 7.93 (5.55–10.31) 12.92 (9.04–16.79) 6.15 (6.15–6.14) 6.96 (4.87–9.05) 4.58 (3.21–5.95)
80 1 15.06 (10.54–19.57) 70.33 (74.85–65.82) 10.98 (7.68–14.27) 7.66 (5.36–9.96) 15.08 (10.56–19.60) 7.37 (7.37–7.36) 6.79 (4.75–8.83) 4.46 (3.12–5.80)
4 15.23 (10.66–19.79 ) 68.73 (73.29–64.16) 11.29 (7.90–14.68) 7.88 (5.52–10.25) 15.25 (10.67–19.82) 7.25 (7.26–7.25) 6.98 (4.88–9.07) 4.58 (3.21–5.96)
12 15.72 (11.01–20.44) 63.79 (68.50–59.07) 12.3(8.61–15.99) 8.59 (6.02–11.17) 15.75 (11.02–20.47) 6.9 (6.90–6.89) 7.57 (5.30–9.84) 4.98 (3.48–6.47)
95 1 16.33 (11.43–21.23) 76.08 (80.98–71.18) 11 (7.70–14.31) 7.68 (5.38–9.99) 16.35 (11.45–21.26) 7.95 (7.96–7.95) 6.83 (4.78–8.87) 4.48 (3.14–5.83)
4 16.53 (11.57–21.48) 74.38 (79.33–69.42) 11.32 (7.92–14.72) 7.9 (5.53–10.27) 16.55 (11.59–21.52) 7.83 (7.84–7.83) 7.01 (4.91–9.12) 4.6 (3.22–5.99)
12 17.1 (11.97–22.22) 69.12 (74.24–63.99) 12.34 (8.64–16.04) 8.62 (6.03–11.20) 17.12 (11.98–22.26) 7.46 (7.46–7.45) 7.61 (5.33–9.89) 5 (3.50– 6.50)
Note. The basic DOTS coverage (δmax) and delay in treatment (1/θ) were both varied. Numbers in parentheses were calculated when the cost per patient with TB increased or reduced by 30%.
DALY, disability-adjusted life-year; NPV, net present value; QALY, quality-adjusted life-year; TSI, Torres Straits Islands.
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Fig. 3 – Sensitivity analysis, in which the parameters are deﬁned in the Supplementary Material found at http://dx.doi.org/10.
1016/j.jval.2014.11.008, with “South Fly” corresponding to (1,1) and “Torres Strait Islands” to (2,2). PNG, Papua New Guinea;
PRCC, Partial rank correlation coefﬁcient; TSI, Torres Strait Islands.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 1 8 0 – 1 8 8186Table 2, however, presents a high level of robustness in our
conclusions irrespective of what direction the true cost would
go. First, from an Australian viewpoint, a 95% basic DOTS
expansion in South Fly remains the most preferred interven-
tion under the CBA framework for Australia, yielding a net
beneﬁt in the range of $79 million to $69 million (column 4).
Likewise, under the CUA framework, this intervention is also
the most cost-effective. For example, the average cost per
DALY averted is in the order of $8,000 to $15,000 (column 5),
being far lower than the threshold of $49,000 [55–57], while the
average cost per QALY ranges from $5,500 to $10,000, being
much less than the lower bound of the suggested threshold of
$35,000 [46], or the estimated threshold of $40,000 [52]. Second,
from an ODA viewpoint, it still costs less than $10 per DALY
averted or less than $7 per QALY saved (columns 9 and 10) in
PNG regardless of the level of coverage or what direction the
cost goes. Therefore, the support for the control of TB in PNG
still fairs well under uncertainty, and results from our epide-
miological model and economic evaluation are robust under
sensitivity analysis.Discussion
Since the early 1990s, DOTS has been promoted as an effective
treatment for new smear- positive cases of TB [63]. Despite being
one of the Millennium Development Goals and later being ranked
as one of the top 10 best health buys in developing countries [58],
progress in DOTS implementation and expansion in developing
countries is still far from adequate. This slow progress is drivenmostly by a lack of required resources, with the ﬁnancial cost
disproportionately born by poor developing countries because of
their high prevalence of TB. Our analysis demonstrates that there
are substantial domestic gains for Australia, a well-resourced
developed country, in strengthening TB control in PNG, its lower-
resourced neighbor. Furthermore, from a donor point of view, this
assistance is very effective because it ranks extremely well
among the top ten best health buys in developing countries,
contributing to the achievement of Millennium Development
Goals [58].
Our study has at least one limitation. We did not take into
account the impact of multidrug-resistant tuberculosis and HIV.
There are two reasons for this. We focus on basic DOTS expan-
sion because it is considered the “cornerstone” of the TB control
strategy in any country [12]. This is especially true for a country
such as PNG where DOTS coverage is incredibly low while
supporting services and resources are very inadequate. It is also
clear that adding multidrug-resistant tuberculosis and HIV will
require us to use a more elaborate stochastic spatial model,
which, due to limited information about their prevalence, is best
left as a topic for future research.
Our study has a number of strengths. First, to our knowledge,
our model is the ﬁrst that takes into account the impact of two-
way population movements from a high-burden developing
country to a low-burden developed country, with an economic
analysis showing that extending treatment in the high-burden
area is mutually beneﬁcial. Second, we use a spatial model to
keep track of TB spread between two countries due to travel,
which was built to ﬁt historical data and trends appropriately.
Third, we apply both CUA and CBA to estimate cost per DALY
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 1 8 0 – 1 8 8 187averted, cost per QALY saved, and the NPV of the basic DOTS
intervention to represent perspectives from both the health
sector and the whole economy, as well for aid effectiveness.
Although our results are not directly generalizable to other
countries because of differences in underlying epidemiological
and economic characteristics, we suspect that studies applying a
similar model approach to countries with similar substantive
differences in TB prevalence would likely generate comparable
results.
Overall, our study suggests that where countries with major
disparities in both TB burden and health system resourcing
border each other or are linked by population movements such
as migration, investments by well-resourced, low-burden
countries in TB control in high-burden, low-resourced neigh-
bors are likely of mutual beneﬁt, resulting in net gains on both
sides of the border as well as across the region as a whole. The
high relative cost of treatment in well-resourced settings
means that beneﬁts exceed the costs of even a large-scale
expansion of control programs in low-resourced areas. Based
on these models and the limited available data for the PNG–
Australia border region, Australia would beneﬁt from invest-
ment in TB control in PNG, and the beneﬁts are greater the
greater the investment. These models would be of relevance to
other regions where such disparities and connections exist,
and could be used in building the case for appropriate invest-
ment in TB control globally.
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